SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-276327
Filing Date
2019-10-28
Accepted
2019-10-28 17:09:46
Documents
14
Period of Report
2019-10-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d825784d8k.htm   iXBRL 8-K 31775
2 EX-99.1 d825784dex991.htm EX-99.1 18390
6 GRAPHIC g825784g1028222751357.jpg GRAPHIC 4763
  Complete submission text file 0001193125-19-276327.txt   187257

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20191028.xsd EX-101.SCH 3053
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20191028_lab.xml EX-101.LAB 18140
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20191028_pre.xml EX-101.PRE 11397
13 EXTRACTED XBRL INSTANCE DOCUMENT d825784d8k_htm.xml XML 3365
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 191173777
SIC: 2834 Pharmaceutical Preparations